Marrone Bio Innovations, Inc. (MBII) Analysts See $-0.04 EPS

July 14, 2018 - By Victoria Pittman

Marrone Bio Innovations, Inc. (NASDAQ:MBII) LogoInvestors sentiment increased to 5.5 in 2018 Q1. Its up 4.93, from 0.57 in 2017Q4. It is positive, as 1 investors sold Marrone Bio Innovations, Inc. shares while 1 reduced holdings. 6 funds opened positions while 5 raised stakes. 78.12 million shares or 565.72% more from 11.74 million shares in 2017Q4 were reported.
Hanson Mcclain holds 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII) or 10,000 shares. 31,936 are owned by Northern Trust. Raymond James Inc holds 11,061 shares. State Street Corp stated it has 10,800 shares. 2,000 were accumulated by Carroll Fincl Assoc. Morgan Stanley has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Ogorek Anthony Joseph Ny Adv holds 300 shares or 0% of its portfolio. Blackrock Incorporated has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Waddell And Reed Financial has 0.11% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Planning Ltd Liability Company holds 0.02% or 33,079 shares in its portfolio. Vanguard Grp Inc Incorporated holds 0% or 1.05M shares in its portfolio. Barclays Plc invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). 10.35M are owned by Ardsley Advisory. Bluecrest Management holds 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 12,428 shares. Geode Cap Mngmt Ltd reported 89,410 shares.

Since February 5, 2018, it had 1 insider buy, and 0 selling transactions for $5.00 million activity.

Analysts expect Marrone Bio Innovations, Inc. (NASDAQ:MBII) to report $-0.04 EPS on August, 13.They anticipate $0.21 EPS change or 84.00 % from last quarter’s $-0.25 EPS. After having $-0.04 EPS previously, Marrone Bio Innovations, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.52% or $0.01 during the last trading session, reaching $1.92. About 174,618 shares traded. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 48.33% since July 14, 2017 and is uptrending. It has outperformed by 35.76% the S&P500.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally. The company has market cap of $212.10 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. It currently has negative earnings. The company's products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

More important recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Globenewswire.com which released: “Marrone Bio Innovations Joins the Russell 2000 Index” on June 25, 2018, also Bizjournals.com published article titled: “Why Marrone Bio is sponsoring a cannabis-growing competition”, Nasdaq.com published: “Marrone Bio Innovations to Host Virtual Roadshow Webinar on July 26th, 2018” on July 12, 2018. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) was released by: Investorideas.com and their article: “(NASDAQ: $MBII) News: Grandevo® CG and Venerate® CG for Pest Insect and Mite Control Cleared for Use on …” with publication date: June 28, 2018.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.